Respuesta :
Regular use of ivermectin for Covid-19 prophylaxis reduced Covid-19 mortality by 92% in a dose-response manner.
BACKGROUND:
We have previously shown that ivermectin, used as prophylaxis for coronavirus disease 2019 (COVID-19), is associated with reduced COVID-19 infection and hospitalization, and mortality. The aim of this study was to determine whether regular use of ivermectin affected his level of protection against COVID-19 and related outcomes, and to enhance the efficacy of ivermectin by demonstrating a dose-response relationship. did.
METHOD:
An exploratory analysis of this prospective observational study included a program of ivermectin at a dose of 0.2 mg/kg/day for 2 consecutive days every 15 days for 150 days. Here is the definition of regularity:
A regular user received her 180 mg or more of ivermectin, and an irregular user received up to 60 mg of ivermectin throughout the program. After multivariate adjustment, comparisons were made between nonusers (those not using ivermectin) and regular and infrequent users. We calculated and compared the risk of COVID-19 infection and death from COVID-19 using the full city database. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality.
RESULT:
Of his 223,128 subjects in Itajai City, 159,560 said he was 18 years of age or older and free of COVID-19 as of July 7, 2020. Of the ivermectin users, 33,971 (29.8%) used it sparingly (up to 60 mg) and 8,325 (7.3%) used it regularly (180 mg and above).
The rest of his 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower in normal users (3.40%) than in non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0, 58; p<0.0001 ) and infrequent users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p<0.0001). Infrequent users had a 32% lower infection rate than non-users (RR: 0.68; 95% CI: 0.64-0.73; p<0.0001).
Among COVID-19 participants, regular users were older and had higher prevalence of type 2 diabetes and hypertension than casual or non-regular users. Matching analysis after PSM included 283 subjects in each group of non-regular and regular users among regular and non-regular users, and 1,542 subjects among non-regular and non-regular users. rice field. 100% reduction in hospital admissions for regular users compared to infrequent users
To learn more ivermectin click below-
https://brainly.com/question/4107066
#SPJ4
